Infection or cure? Scientists from Tel Aviv University and the University of Glasgow genetically modified the Toxoplasma gondii to bring a protein inside neurons. The novelty of using a protozoan that can travel from the gut to parasitize the CNS contrasts with the possibility of causing a disease. The scientists are already working on how to avoid it. Read More
Chengdu Westgene Biopharma Co. Ltd. (Westgene) has received approval from both China's National Medical Products Administration (NMPA) and the FDA for its therapeutic cancer vaccine WGc-043 to enter first-in-human trials. Read More
Researchers at Leiden University have synthesized semisynthetic guanidino lipoglycopeptides with in vitro and in vivo activity gram-positive bacteria, including methicillin-resistant and vancomycin-resistant Staphylococcusaureus. Read More
Researchers from Indiana University have presented data from a study that aimed to assess the potential of suppressing GABA metabolism through inhibition of its degradation enzyme, GABA aminotransferase (GABA-AT), as novel analgesic strategy. The effect of next-generation GABA-AT inhibitor OV-329 was assessed in C57BL/6J mice that were intraperitoneally injected with paclitaxel to generate neuropathic nociception. Treatment with OV-329 attenuated the development and maintenance of paclitaxel-induced mechanical hypersensitivity. Read More
Shanghai Meiyue Biotech Development Co. Ltd. has discovered MAPK p38 inhibitors reported to be useful for the treatment of arthritis, psoriasis, systemic lupus erythematosus, diabetes, cancer, atherosclerosis and Alzheimer's disease. Read More
After receiving Orphan Drug Designation earlier this year, Satellos Bioscience Inc. announced that the FDA has granted Rare Pediatric Disease Designation to SAT-3247 for the potential treatment of Duchenne muscular dystrophy (DMD). Read More
From no hope to viable treatments, BioWorld is there to cover the breakthroughs in medicine. Listen to Randy Osborne explain why the BioWorld team is ‘always on the lookout for what's next.’ Read More
Vicore Pharma AB has identified compounds acting as angiotensin AT2 receptor (AGTR2) agonists reported to be useful for the treatment of fibrosis, heart failure, pulmonary hypertension, respiratory tract infection, myocardial infarction, pre-eclampsia, autoimmune and chronic kidney disease. Read More
Chengdu Chipscreen Pharmaceutical Ltd. has divulged aminothiophene compounds acting as viral replication inhibitors reported to be useful for the treatment of hepatitis B (HBV) virus infection. Read More
Researchers from Royal Children's Hospital, the University of Melbourne and affiliated organizations published data from a study that aimed to investigate the potential of benfotiamine, which is a lipid soluble precursor to thiamine, for the treatment of inflammation related dystrophic pathology in patients with Duchenne muscular dystrophy (DMD). Read More
Shanghai Yiweikang Pharmaceutical Co. Ltd. has described ectonucleotide pyrophosphatase/phosphodiesterase family member 1 (ENPP1) inhibitors reported to be useful for the treatment of cancer, autoimmune disease, inflammatory and immunological disorders. Read More
Angel Pharmaceuticals Co. Ltd. has prepared and tested protein mono-ADP-ribosyltransferase TIPARP (PARP-7; ARTD14) inhibitors reported to be useful for the treatment of cancer. Read More
A recent study in PLoS One by researchers from Cincinnati Children’s Hospital Medical Center has evaluated the preclinical long-term safety of human A gamma-globin gene-carrying GbGM LV in wild-type mice. Read More
